Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 29

1.

Analyzing Nanotheraputics Based Approaches For The Management Of Psychotic Disorders.

Annu, Rehman S, Md S, Baboota S, Ali J.

J Pharm Sci. 2019 Sep 6. pii: S0022-3549(19)30560-X. doi: 10.1016/j.xphs.2019.08.027. [Epub ahead of print] Review.

PMID:
31499066
2.

Identification of significant protein markers by mass spectrometry after cells co-treated with different drugs: an in vitro survey platform.

Wu YJ, Huang CH, Hsieh TJ, Tseng WL, Lu CY.

Rapid Commun Mass Spectrom. 2019 Sep 9. doi: 10.1002/rcm.8582. [Epub ahead of print]

PMID:
31498944
3.

Abnormal liver function tests in acne patients receiving isotretinoin.

Pona A, Cardenas-de la Garza JA, Haidari W, Cline A, Feldman SR, Taylor SL.

J Dermatolog Treat. 2019 Sep 9:1-4. doi: 10.1080/09546634.2019.1662882. [Epub ahead of print]

PMID:
31498706
4.

Classification Scheme for Incident Reports of Medication Errors.

Shiima Y, Wong ZS.

Stud Health Technol Inform. 2019 Aug 9;265:113-118. doi: 10.3233/SHTI190148.

PMID:
31431586
5.

[Fracture healing gone astray : Importance of nonsurgical influencing factors].

Hesse E.

Unfallchirurg. 2019 Jul;122(7):498-499. doi: 10.1007/s00113-019-0680-2. German. No abstract available.

PMID:
31289911
6.

Management of common adverse events related to first-line dacomitinib use in EGFR mutation-positive non-small-cell lung cancer: a pooled safety analysis.

Zhou Q, Wu YL, Corral J, Nakagawa K, Garon EB, Sbar EI, Wang T, Sandin R, Noonan K, Gernhardt D, Mok TS.

Future Oncol. 2019 May;15(13):1481-1491. doi: 10.2217/fon-2018-0944. Epub 2019 Mar 6.

PMID:
30839234
7.

eToxPred: a machine learning-based approach to estimate the toxicity of drug candidates.

Pu L, Naderi M, Liu T, Wu HC, Mukhopadhyay S, Brylinski M.

BMC Pharmacol Toxicol. 2019 Jan 8;20(1):2. doi: 10.1186/s40360-018-0282-6.

8.

Variability of surgical prophylaxis in penicillin-allergic children.

Butler DF, Lee BR, Suppes S, Sandritter T, Newland JG, Harte L, Goldman JL.

Infect Control Hosp Epidemiol. 2018 Dec;39(12):1480-1483. doi: 10.1017/ice.2018.244.

PMID:
30526715
9.

Cutaneous manifestations of hematologic malignancies the experience of an Italian dermatology department.

Merlo G, Cozzani E, Canale F, Miglino M, Gambella M, Burlando M, Parodi A.

Hematol Oncol. 2019 Aug;37(3):285-290. doi: 10.1002/hon.2569. Epub 2018 Dec 14.

PMID:
30485475
10.

Serum retinyl esters are positively correlated with analyzed total liver vitamin A reserves collected from US adults at time of death.

Olsen K, Suri DJ, Davis C, Sheftel J, Nishimoto K, Yamaoka Y, Toya Y, Welham NV, Tanumihardjo SA.

Am J Clin Nutr. 2018 Nov 1;108(5):997-1005. doi: 10.1093/ajcn/nqy190.

PMID:
30475970
11.

Therapeutic monitoring of antiepileptic drugs in comatose patients.

Charfi R, Mizouri R, Ben Sassi M, Eljebari H, Jebabli N, Ben Salem F, Zerei S, Mrabet A, Daghfous R, Klouz A, Salouage I, Gaies E, Trabelsi S.

Tunis Med. 2018 Feb;96(2):129-134.

12.

Effectiveness of dapagliflozin versus comparators on renal endpoints in the real world: A multicentre retrospective study.

Fadini GP, Solini A, Manca ML, Penno G, Gatti A, Anichini R, Del Prato S, Avogaro A; DARWIN-T2D Network.

Diabetes Obes Metab. 2019 Feb;21(2):252-260. doi: 10.1111/dom.13508. Epub 2018 Sep 21.

13.

Opportunities and Challenges in Cardiovascular Pharmacogenomics: From Discovery to Implementation.

Roden DM, Van Driest SL, Wells QS, Mosley JD, Denny JC, Peterson JF.

Circ Res. 2018 Apr 27;122(9):1176-1190. doi: 10.1161/CIRCRESAHA.117.310965. Review.

14.

Importance of including harms as well as benefits in all clinical trials.

Tugwell P, Knottnerus JA.

J Clin Epidemiol. 2018 Mar;95:v-vi. doi: 10.1016/j.jclinepi.2018.02.004. No abstract available.

PMID:
29477217
15.

Critical Care Pharmacists and Medication Management in an ICU Recovery Center.

Stollings JL, Bloom SL, Wang L, Ely EW, Jackson JC, Sevin CM.

Ann Pharmacother. 2018 Aug;52(8):713-723. doi: 10.1177/1060028018759343. Epub 2018 Feb 18.

16.

Bias from restricting to live births when estimating effects of prescription drug use on pregnancy complications: A simulation.

Suarez EA, Landi SN, Conover MM, Jonsson Funk M.

Pharmacoepidemiol Drug Saf. 2018 Mar;27(3):307-314. doi: 10.1002/pds.4387. Epub 2018 Jan 17.

PMID:
29341340
17.

Strengthening standards, transparency, and collaboration to support medicine evaluation: Ten years of the European Network of Centres for Pharmacoepidemiology and Pharmacovigilance (ENCePP).

Kurz X, Perez-Gutthann S; ENCePP Steering Group.

Pharmacoepidemiol Drug Saf. 2018 Mar;27(3):245-252. doi: 10.1002/pds.4381. Epub 2018 Jan 11. No abstract available.

18.

Bias from outcome misclassification in immunization schedule safety research.

Newcomer SR, Kulldorff M, Xu S, Daley MF, Fireman B, Lewis E, Glanz JM.

Pharmacoepidemiol Drug Saf. 2018 Feb;27(2):221-228. doi: 10.1002/pds.4374. Epub 2018 Jan 2.

19.

Methods for time-varying exposure related problems in pharmacoepidemiology: An overview.

Pazzagli L, Linder M, Zhang M, Vago E, Stang P, Myers D, Andersen M, Bahmanyar S.

Pharmacoepidemiol Drug Saf. 2018 Feb;27(2):148-160. doi: 10.1002/pds.4372. Epub 2017 Dec 28. Review. Erratum in: Pharmacoepidemiol Drug Saf. 2018 Mar;27(3):356.

20.

Is patient exposure preapproval and postapproval a determinant of the timing and frequency of occurrence of safety issues?

Pacurariu AC, Hoeve CE, Arlett P, Genov G, Slattery J, Sturkenboom MCJM, Straus SMJM.

Pharmacoepidemiol Drug Saf. 2018 Feb;27(2):168-173. doi: 10.1002/pds.4359. Epub 2017 Dec 26.

PMID:
29278866

Supplemental Content

Loading ...
Support Center